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Abstract: 
Background: 
There exists a sub group of patients with uremic cardiomyopathy who experience 
resolution of heart failure following hemodialysis. 
It has been hypothesized that these patients are fluid overloaded, and following 
hemodialysis , show improvements in cardiac  geometry and function. We wanted to 
study their clinical, biochemical and echocardiographic features to define any other 
additional characteristics. 
Aim: To define characteristics of reversible systolic dysfunction. 
Methods: 
  We studied 72 patients with chronic kidney disease on hemodialysis of  whom 52 
presented with congestive heart failure, over a period of 190 days. We studied their 
echocardiographic profile and blood biochemistry parameters including troponin I and C 
reactive protein. 
Results: 
There were 29 patients with systolic dysfunction(LVEF≤40%). Twenty three patients 
with preserved systolic function, had diastolic dysfunction. Of the 29 patients with 
systolic dysfunction, 10 patients had significant improvement in NYHA functional class , 
and left ventricular dimensions (LVIDd:59.8±2.6 mm to 55.9±2 mm and LVIDs:51.8±1.8 
mm to 34±1.2 mm; p<0.001) with significant increase in left ventricular ejection 
fraction(30.5±5% to 50.1±4%; p<0.001). These patients had the highest serum levels of 
troponin I (p=0.024) which decreased significantly with recovery of cardiac function. In 
the patients with persistent systolic dysfunction and in the patients with diastolic 
function, the troponin I remained high. The troponin I was significantly lesser in the 
control group(p=0.002) 
Conclusions: 
A sub group of patients with uremic cardiomyopathy demonstrated reversible left 
ventricular systolic  dysfunction, and high levels of serum troponin I levels at 
presentation, which regressed with recovery of ventricular function. 
 
Key Words: Uremic cardiomyopathy, Chronic kidney disease, Troponin I, Dilated 
cardiomyopathy 
Abbreviations: LV:Left Ventricle, LVIDd: Left ventricular internal diameter in diastole, 
LVIDs: Left ventricular internal diameter in systole, IVSd: interventricular septal 
thickness in diastole, PWDd: posterior wall diameter in diastole, LVEF: Left ventricular 
ejection fraction, PASP: Pulmonary artery systolic pressure, LSD: least significant 
difference, NYHA: New york heart association, CAD: Coronary artery disease. 
 
 
 
 
 
 
 
 
  
 
 
 
INTRODUCTION:  Uremic cardiomyopathy 1,2,3, presents as  congestive cardiac failure 
due to systolic or diastolic dysfunction. Systolic dysfunction can be transient , due to 
increased pre-load , which  hemodialysis can improve 4,5,6. We studied   these patients 
with reversible ventricular dysfunction. 
METHODS:  
Study Design: We studied 72 consecutive patients with chronic kidney disease , of whom 
52  presented with congestive heart failure, and  20 were controls. The study period was 
from April 2007 to October 2007. The study was approved by the Institutional Ethics 
Committee, and written consent was obtained from the study patients. All patients 
underwent clinical examination, electrocardiogram, hematological and biochemistry tests 
and 2D transthoracic echocardiogram. .  
Inclusion criteria: Congestive heart failure according to Framingham criteria, estimated 
glomerular filtration rate < 60ml/min/1.73 m2 for 3 months 7. Presence of coronary artery 
disease was defined as>70% stenosis on coronary angiogram or presence of infarction 
documented on electrocardiogram. .   
 Exclusion criteria : a) acute coronary syndrome within 3 months b) chronic stable 
angina c) chest pain in the peridialysis period d) major cardiovascular surgery e)severe 
valvular heart disease f) pericardial disease and  g) malignancy 
Assessment methods: Pre dialysis and post dialysis weight was recorded on the same 
weighing machine. Dry weight was established for each patient on a trial and error basis; 
defined as the weight below which the patient suffered frequent hypotensive episodes 
during the latter part of the dialysis session, and experienced malaise, cramps and 
dizziness post-dialysis.  
ASSAYS: All blood samples were drawn before hemodialysis.  
Cardiac troponin I was measured with the IMMULITE troponin I assay ( Diagnostic 
Products Corporation; Los Angeles, CA) .The analytical sensitivity was 0.1 ng/ml. The 
extended range  C reactive protein was determined by a nephelometric analyzer ( Dade-
Behring, Newark, DE) by the particle enhanced turbidometric immunoassay technique( 
PETIA). The measurement range of the assay was 0.5 mg/L to 250 mg/L.  
ECHOCARDIOGRAPHY: The General Electric Vivid 3 ultrasound machine ( 
Milwaukee, Wisconsin) equipped with a 2.5 MHz frequency transducer was used. Two 
dimensional measurements were performed as recommended by the American Society of 
Echocardiography 8, prior to hemodialysis and at discharge.  Values were indexed to 
body surface area. Systolic dysfunction was defined as LVEF≤40%. Diastolic 
dysfunction was defined as (E:A ratio<1, E deceleration time>220 ms) or restrictive 
filling (E:A >2, E:A between 1 and 2 with E deceleration time <150 ms) from the pulsed 
Doppler transmitral flow. Tissue Doppler imaging of mitral annular velocities with an 
E/Ea ratio >10 further defined diastolic dysfunction.9 
FOLLOW-UP: All patients were followed over a period of 190 days. Routine 
hematological, biochemical tests ,C reactive protein and troponin I assays were done. 
  
Dialysis Techniques: .All 52 patients were on long-term hemodialysis with 3 cycles/ 
week for 4-5 hours, using Baxter 1550( Deerfield, IL, USA) machine, a 1.2 to 1.7 m2 
hollow fiber polysulfone dialyser and bicarbonate- buffered dialysis solution.. The 
patients with severe cardiac failure ie.NYHA class 4  were subjected to ultrafiltration just 
after hemodialysis, at a rate of 0.5-1L/hr until clinical resolution of cardiac failure.  
STATISTICAL ANALYSIS:  
Continuous variables were expressed as mean±SD. Categorical variables were expressed 
as %. There were 29 patients with systolic dysfunction based on LVEF≤40% and 23 
patients with left ventricular diastolic dysfunction and preserved systolic function ie. 
LVEF>40%. Based on initial and repeat echocardiogram patients were assigned to 3 
different groups. The first group consisted of patients who had initially presented with 
systolic dysfunction but demonstrated recovery of systolic function in the repeat 
echocardiogram. The second group consisted of patients who had consistent systolic 
dysfunction even in the repeat echocardiogram and the third group were patients with 
preserved systolic function. Age, Hb%, blood urea, creatinine, glomerular filtration rate, 
C reactive protein and troponin I at baseline were considered as variables that could 
possibly predict the group of the patients. LVIDd, LVIDs, IVSd, LVPWd, PASP and 
LVEF were the outcome variables that differentiated the group membership of the 
patients. The mean baseline predictors and outcomes as well as the change in outcome 
measures over the 2 assessments were compared between groups using ANOVA. Post-
hoc LSD test  was done whenever ANOVA was significant. The association of 
categorical variables and groups was examined using the chi-square test. Spearman’s 
correlation co-efficients assessed the strength of association between the predictor 
variables and the outcome variables in each group. Discriminant function analysis was 
used to identify variables that could differentiate the 3 groups. Further, multivariate 
logistic regression analysis identified the variables that increased the odds of a patient 
belonging to the group with reversible systolic dysfunction. The tests were considered 
significant if p<0.05. All analyses were carried out using SPSS version 13.0 (SPSS Inc, 
Chicago, Ill). 
RESULTS: 
The baseline patient clinical and echocardiographic characteristics are listed in Table:1. 
The mean age of the entire study group was 47.7±6.53 years. There were 43(59.7%) 
males and 29(40.2%) females.  There were 29 patients who presented with congestive 
heart failure, with LVEF<40%. Repeat echocardiogram identified 10 patients as 
belonging to group 1 with complete recovery of left ventricular function. The 19 patients 
who had persistent systolic dysfunction with LVEF<40% were labeled group 2, and the 
23 patients with diastolic dysfunction  and LVEF> 40% were labeled group 3. There was 
no significant difference in age between the 3 groups. None of the patients in all 3 groups 
were grossly edematous, with  no significant difference in weight. The C reactive protein 
and troponin I were significantly higher for groups 1 and 2 as compared to group 3 
(p<0.001). Post-hoc tests revealed that the left ventricular dimensions in diastole and 
systole were significantly higher for groups 1 and 2 (p<0.001) and the left ventricular 
ejection fraction was significantly lower for groups 1 and 2 (p<0.001). The 
interventricular septal thickness and free wall thickness were highest in  group 3 as 
compared to groups 1 and 2, but not significantly so. The pulmonary systolic pressures 
were lowest in group 1 and highest in group 2. The 20 patients without heart failure were 
age and sex matched with the heart failure group. There were 11 hypertensives, 5 
diabetics and 6 CAD patients. They all had LV hypertrophy, normal LV dimensions and 
LVEF. When the mean troponin I value for group 3 (1.13±0.53) was compared with the 
patients without  heart failure (0.74±0.39), it was significantly higher in group 3 
(p=0.002), demonstrating that the troponin I elevations are significantly higher in patients 
with heart failure. 
 
The patient characteristics on follow-up are listed in Table:2. 
On follow-up, there was a significant improvement in clinical signs of heart failure. The 
NYHA class 3 and 4 patients shifted to class1 in group 1. There was no change in groups 
2 and 3. There was no significant change in dry weight post dialysis and in between 
dialysis cycles. ANOVA for difference in measure changes between the groups showed 
that in group 1, there was a significant decrease in left ventricular dimensions in diastole 
and systole (both at p<0.001), pulmonary systolic pressures (p=0.03) and increase in left 
ventricular ejection fraction (p<0.001). The reduction in pulmonary systolic pressures 
was significant for group 1 as compared to groups 2 and 3 (p=0.044).  
  Discriminant  function analysis showed that a model with just baseline troponin I could 
best differentiate between the groups . The correct classification based on discriminant 
function was 60% in group 1, 52.6% in group 2 and 87% in group 3 based on troponin I. 
Overall 69.2% patients were classified correctly. The sample size being small and not 
optimal for discriminant function analysis, multivariate logistic regression which is a 
more robust technique was done. Groups 2 and 3 for whom the disease state did not 
change were considered as a single reference group and the odds of group 1 with respect 
to the baseline troponin I values was computed. Higher values of troponin I  alone tended 
to increase the odds of belonging to group 1; odds ratio:10.94 (95%CI:0.80 - 150.0) ; 
p=0.073. The R2 value for this model was 0.46. The repeat C reactive protein  and 
troponin I assays done after 6 months were significantly lesser for patients in group 1 
(p=0.002). There was a non significant decrease in group 3 and no change in group 2. 
There was no change in LV dimensions, LV hypertrophy , LVEF, troponin I and C 
reactive protein levels in the patients without heart failure on follow-up.  
 
 
 
 
 
DISCUSSION: 
Uremic cardiomyopathy is a distinct clinical entity 3. Endomyocardial biopsies have 
shown severe myocyte hypertrophy, disarray and interstitial fibrosis 3,10,22 . In our 
patients, group 3 had maximum left ventricular hypertrophy. Group 2 had increased 
pulmonary pressures, persistent left ventricular dilatation and  reduced LVEF. The 
patients in group 1 had lesser degree of left ventricular hypertrophy, lesser pulmonary 
pressures and lower baseline LVEF than group 2, which improved on follow-up.  
There are reports of improvements in left ventricular function following hemodialysis. 4,5,6 
Nocturnal hemodialysis showed a sustained increase in  left ventricular ejection fraction.5 
Persistent ultrafiltration during hemodialysis demonstrated regression in cardiac size and 
improvements in ejection fractions 6  in patients with significant fluid overload. All our 
patients (groups 1,2 and 3) were subjected to prolonged ultrafiltration during 
hemodialysis. None of them were fluid overloaded.  
The cardiac troponin I is specific for detection of myocardial injury in chronic renal 
failure.12,13,15  Elevated troponin levels independently predicted increased left ventricular 
mass and systolic dysfunction in patients with chronic kidney disease 16,17,18 ,with high 
positive predictive values for left ventricular hypertrophy and high negative predictive 
values for systolic dysfunction 17,18,23. All our patients in group 2 had ventricular 
hypertrophy , systolic dysfunction and elevated troponin I  levels at follow up.  Continued 
rise in  troponin I in group 3 can be explained by persistent left ventricular hypertrophy.  
In reversible conditions like myocarditis 24 and septic shock 25 transient ventricular 
dilatation and reduced function was associated with transient rise of troponin I. The 
failure of continued release was due to absence of remodeling and  release of structurally 
bound troponin, reflecting ‘ reversible injury’.  
In our study, raised troponin I which regressed at follow up increased the odds of the 
patient having reversible systolic dysfunction. . The levels of C-reactive protein which 
predict  cardiovascular morbidity and mortality in chronic kidney disease was 6mg/L 11,19 
. The levels in our patients reflect low  grade inflammation. The regression of C reactive 
protein levels in parallel with troponin I levels in group 1 patients, with recovery of left 
ventricular systolic function  may generate a hypothesis that  reversible myocardial injury 
exists in a subgroup of uremic cardiomyopathy, requiring large scale studies to explore 
this interesting finding  
 
STUDY LIMITATIONS:  
As the sample size is small, we have not been able to define a predictive value of 
troponin I for left ventricular dysfunction. 
We have also not performed endomyocardial biopsies in our patients due to logistic 
constraints. 
. 
CONCLUSIONS: 
In patients dilated uremic cardiomyopathy, there exists a sub-group with reversible left 
ventricular systolic dysfunction characterized by an absence of significant remodeling, 
and significantly higher levels of serum cardiac troponin I, which  regress with recovery 
of cardiac function. 
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Table 1 BASELINE PATIENT CHARACTERISTICS 
 
 
 
 Group1 
(n=10) 
Group2 
(n=19) 
Group3 
(n=23) 
P value  
 
Predictor Variables 
     
Age(Yrs)                 44.5±8.5      47.7±5.4      49.3±6.2      NS  
Sex(M/F)   6/4              11/8             14/9          NS  
BP(mmHg)                         
 
141±10.0     
86±7.0         
144±10.8  
88±6.0         
152±12.0   
90±8.0            
NS 
NS 
 
Weight(Kg)  66±3            69±2            69±4             NS  
NYHA3/4(%) 100%          99% 86%              NS  
CRP(mg/L) 3.0±0.7        2.8±0.84      1.3±0.43        <0.001  
TropI(ng/ml) 2.3±0.35      2±0.28         1.2±0.52       <0.001  
 
Outcome Variables 
     
LVIDd(mm) 59±2.7         59±3.2*       53±2*            <0.001  
LVIDs(mm) 51±4.5         49±6.4*       36±5.5*         <0.001  
IVSd(mm)  12±0.8         12±0.9         13±1.2          NS  
LVPWd(mm) 12.0±0.8      12.0±0.9      12.9±1.2       NS  
PASP(mmHg) 43.8±5.3      45.3±4.5      44.0±3.4*       NS  
LVEF(%)   30.5±5.5  35.3±5.8*    52.7±5.4*      <0.001  
LVDD(%)  10.0   89.5             91.3            <0.001  
 
P = level of significance from ANOVA for comparison of means between groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 CLINICAL AND ECHOCARDIOGRAPHIC CHARACTERISTICS ON 
FOLLOW-UP 
 
 
 Group1 
(n=10) 
Group2 
(n=19) 
Group3 
(n=23) 
P value 
 
Predictor Variables 
    
BP(mmHg)                         
 
120±8   
80±4                  
122±7   
82±6                  
124±6 
82±7            
 
0.04 
NYHA1/2(%)    99.3                   0 15    <0.001 
Weight(Kg)      64±2                  68±3                  66±2            NS 
CRP(mg/L)         1.2±0.2             1.9±0.7              1.1±0.5        0.004 
TropI(ng/ml) 0.2±0.01            1.8±0.3              0.5±0.05    <0.001 
 
Outcome Variables 
    
LVIDd(mm)  55±2.1               59±3.7*             54±2.7* <0.001 
LVIDs(mm                   34±2.5               48±8*                37±6.1*   <0.001   
IVSd(mm) 11±1                  12±0.9               13.5±1.5      NS 
LVPWd(mm) 11.5±0.9            12.5±0.8            13±1.4         NS 
PASP(mmHg) 40.8±4.6            43.8±3.7            44.4±3.1*    0.04 
LVEF(%)              50±3.1               37±7.2*             50±9*   <0.001 
 
P = level of significance from ANOVA for comparison of means between groups 
* mean difference between baseline and follow up significantly different from Group 1 
by post hoc test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
